Akt2 and nucleophosmin/B23 function as an oncogenic unit in human lung cancer cells

Experimental Cell Research

Volumn 317, Issue 7, 2011, Pages 966-975

  Kim, Chung Kwon ^a   Nguyen, Truong L X ^a   Lee, Sang Bae ^a   Park, Sang Bum ^a   Lee, Kyung Hoon ^a   Cho, Sung Woo ^b   Ahn, Jee Yin ^a  

^a Sungkyunkwan University School of Medicine   (South Korea)

^b University of Ulsan College of Medicine   (South Korea)

Author keywords

A549; Akt2; Invasion; Nucleophosmin(B23); Proliferation; Tumorigenesis

Indexed keywords

AGAR; NUCLEOPHOSMIN; PROTEIN KINASE B BETA;

APOPTOSIS; ARTICLE; CANCER CELL; CANCER CELL CULTURE; CANCER GROWTH; CANCER INHIBITION; CANCER SURVIVAL; CARCINOGENESIS; CELL CYCLE PROGRESSION; CELL CYCLE REGULATION; CELL PROLIFERATION; CELL SURVIVAL; CONTROLLED STUDY; HUMAN; HUMAN CELL; LUNG ADENOCARCINOMA; ONCOGENE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN FUNCTION;

EID: 79952452587     PISSN: 00144827     EISSN: 10902422     Source Type: Journal    
DOI: 10.1016/j.yexcr.2010.12.013     Document Type: Article

References (40)

1. Brodbeck D., Cron P., Hemmings B.A. A human protein kinase Bgamma with regulatory phosphorylation sites in the activation loop and in the C-terminal hydrophobic domain. J. Biol. Chem. 1999, 274:9133-9136.
2. Masure S., Haefner B., Wesselink J.J., Hoefnagel E., Mortier E., Verhasselt P., Tuytelaars A., Gordon R., Richardson A. Molecular cloning, expression and characterization of the human serine/threonine kinase Akt-3. Eur. J. Biochem. 1999, 265:353-360.
3. Nakatani K., Sakaue H., Thompson D.A., Weigel R.J., Roth R.A. Identification of a human Akt3 (protein kinase B gamma) which contains the regulatory serine phosphorylation site. Biochem. Biophys. Res. Commun. 1999, 257:906-910.
4. Jiang Z.Y., He Z., King B.L., Kuroki T., Opland D.M., Suzuma K., Suzuma I., Ueki K., Kulkarni R.N., Kahn C.R., King G.L. Characterization of multiple signaling pathways of insulin in the regulation of vascular endothelial growth factor expression in vascular cells and angiogenesis. J. Biol. Chem. 2003, 278:31964-31971.
5. Brognard J., Sierecki E., Gao T., Newton A.C. PHLPP and a second isoform, PHLPP2, differentially attenuate the amplitude of Akt signaling by regulating distinct Akt isoforms. Mol. Cell 2007, 25:917-931.
6. Lee S.B., Xuan Nguyen T.L., Choi J.W., Lee K.H., Cho S.W., Liu Z., Ye K., Bae S.S., Ahn J.Y. Nuclear Akt interacts with B23/NPM and protects it from proteolytic cleavage, enhancing cell survival. Proc. Natl Acad. Sci. USA 2008, 105:16584-16589.
7. Cho H., Mu J., Kim J.K., Thorvaldsen J.L., Chu Q., Crenshaw E.B., Kaestner K.H., Bartolomei M.S., Shulman G.I., Birnbaum M.J. Insulin resistance and a diabetes mellitus-like syndrome in mice lacking the protein kinase Akt2. Science 2001, 292:1728-1731.
8. Easton R.M., Cho H., Roovers K., Shineman D.W., Mizrahi M., Forman M.S., Lee V.M., Szabolcs M., de Jong R., Oltersdorf T., Ludwig T., Efstratiadis A., Birnbaum M.J. Role for Akt3/protein kinase B gamma in attainment of normal brain size. Mol. Cell. Biol. 2005, 25:1869-1878.
9. Dummler B., Tschopp O., Hynx D., Yang Z.Z., Dirnhofer S., Hemmings B.A. Life with a single isoform of Akt: mice lacking Akt2 and Akt3 are viable but display impaired glucose homeostasis and growth deficiencies. Mol. Cell. Biol. 2006, 26:8042-8051.
10. Roy H.K., Olusola B.F., Clemens D.L., Karolski W.J., Ratashak A., Lynch H.T., Smyrk T.C. AKT proto-oncogene overexpression is an early event during sporadic colon carcinogenesis. Carcinogenesis 2002, 23:201-205.
11. Xu X., Sakon M., Nagano H., Hiraoka N., Yamamoto H., Hayashi N., Dono K., Nakamori S., Umeshita K., Ito Y., Matsuura N., Monden M. Akt2 expression correlates with prognosis of human hepatocellular carcinoma. Oncol. Rep. 2004, 11:25-32.
12. Stal O., Perez-Tenorio G., Akerberg L., Olsson B., Nordenskjold B., Skoog L., Rutqvist L.E. Akt kinases in breast cancer and the results of adjuvant therapy. Breast Cancer Res. 2003, 5:R37-R44.
13. Stahl J.M., Sharma A., Cheung M., Zimmerman M., Cheng J.Q., Bosenberg M.W., Kester M., Sandirasegarane L., Robertson G.P. Deregulated Akt3 activity promotes development of malignant melanoma. Cancer Res. 2004, 64:7002-7010.
14. Chan W.Y., Liu Q.R., Borjigin J., Busch H., Rennert O.M., Tease L.A., Chan P.K. Characterization of the cDNA encoding human nucleophosmin and studies of its role in normal and abnormal growth. Biochemistry 1989, 28:1033-1039.
15. Itahana K., Bhat K.P., Jin A., Itahana Y., Hawke D., Kobayashi R., Zhang Y. Tumor suppressor ARF degrades B23, a nucleolar protein involved in ribosome biogenesis and cell proliferation. Mol. Cell 2003, 12:1151-1164.
16. Wu M.H., Yung B.Y. UV stimulation of nucleophosmin/B23 expression is an immediate-early gene response induced by damaged DNA. J. Biol. Chem. 2002, 277:48234-48240.
17. Wu M.H., Chang J.H., Chou C.C., Yung B.Y. Involvement of nucleophosmin/B23 in the response of HeLa cells to UV irradiation. Int. J. Cancer 2002, 97:297-305.
18. Ahn J.Y., Liu X., Cheng D., Peng J., Chan P.K., Wade P.A., Ye K. Nucleophosmin/B23, a nuclear PI(3, 4, 5)P(3) receptor, mediates the antiapoptotic actions of NGF by inhibiting CAD. Mol. Cell 2005, 18:435-445.
19. Grisendi S., Bernardi R., Rossi M., Cheng K., Khandker L., Manova K., Pandolfi P.P. Role of nucleophosmin in embryonic development and tumorigenesis. Nature 2005, 437:147-153.
20. Kurki S., Peltonen K., Latonen L., Kiviharju T.M., Ojala P.M., Meek D., Laiho M. Nucleolar protein NPM interacts with HDM2 and protects tumor suppressor protein p53 from HDM2-mediated degradation. Cancer Cell 2004, 5:465-475.
21. Colombo E., Marine J.C., Danovi D., Falini B., Pelicci P.G. Nucleophosmin regulates the stability and transcriptional activity of p53. Nat. Cell Biol. 2002, 4:529-533.
22. Maiguel D.A., Jones L., Chakravarty D., Yang C., Carrier F. Nucleophosmin sets a threshold for p53 response to UV radiation. Mol. Cell. Biol. 2004, 24:3703-3711.
23. Bertwistle D., Sugimoto M., Sherr C.J. Physical and functional interactions of the Arf tumor suppressor protein with nucleophosmin/B23. Mol. Cell. Biol. 2004, 24:985-996.
24. Brady S.N., Yu Y., Maggi L.B., Weber J.D. ARF impedes NPM/B23 shuttling in an Mdm2-sensitive tumor suppressor pathway. Mol. Cell. Biol. 2004, 24:9327-9338.
25. Kondo T., Minamino N., Nagamura-Inoue T., Matsumoto M., Taniguchi T., Tanaka N. Identification and characterization of nucleophosmin/B23/numatrin which binds the anti-oncogenic transcription factor IRF-1 and manifests oncogenic activity. Oncogene 1997, 15:1275-1281.
26. Korgaonkar C., Hagen J., Tompkins V., Frazier A.A., Allamargot C., Quelle F.W., Quelle D.E. Nucleophosmin (B23) targets ARF to nucleoli and inhibits its function. Mol. Cell. Biol. 2005, 25:1258-1271.
27. Tsao A.S., McDonnell T., Lam S., Putnam J.B., Bekele N., Hong W.K., Kurie J.M. Increased phospho-AKT (Ser(473)) expression in bronchial dysplasia: implications for lung cancer prevention studies. Cancer Epidemiol. Biomark. Prev. 2003, 12:660-664.
28. Balsara B.R., Pei J., Mitsuuchi Y., Page R., Klein-Szanto A., Wang H., Unger M., Testa J.R. Frequent activation of AKT in non-small cell lung carcinomas and preneoplastic bronchial lesions. Carcinogenesis 2004, 25:2053-2059.
29. Mukohara T., Kudoh S., Matsuura K., Yamauchi S., Kimura T., Yoshimura N., Kanazawa H., Hirata K., Inoue K., Wanibuchi H., Fukushima S., Yoshikawa J. Activated Akt expression has significant correlation with EGFR and TGF-alpha expressions in stage I NSCLC. Anticancer Res. 2004, 24:11-17.
30. Bianco R., Shin I., Ritter C.A., Yakes F.M., Basso A., Rosen N., Tsurutani J., Dennis P.A., Mills G.B., Arteaga C.L. Loss of PTEN/MMAC1/TEP in EGF receptor-expressing tumor cells counteracts the antitumor action of EGFR tyrosine kinase inhibitors. Oncogene 2003, 22:2812-2822.
31. Okuzawa K., Franzen B., Lindholm J., Linder S., Hirano T., Bergman T., Ebihara Y., Kato H., Auer G. Characterization of gene expression in clinical lung cancer materials by two-dimensional polyacrylamide gel electrophoresis. Electrophoresis 1994, 15:382-390.
32. Hirano T., Franzen B., Uryu K., Okuzawa K., Alaiya A.A., Vanky F., Rodrigues L., Ebihara Y., Kato H., Auer G. Detection of polypeptides associated with the histopathological differentiation of primary lung carcinoma. Br. J. Cancer 1995, 72:840-848.
33. Bergstralh D.T., Conti B.J., Moore C.B., Brickey W.J., Taxman D.J., Ting J.P. Global functional analysis of nucleophosmin in Taxol response, cancer, chromatin regulation, and ribosomal DNA transcription. Exp. Cell Res. 2007, 313:65-76.
34. Okuda M., Horn H.F., Tarapore P., Tokuyama Y., Smulian A.G., Chan P.K., Knudsen E.S., Hofmann I.A., Snyder J.D., Bove K.E., Fukasawa K. Nucleophosmin/B23 is a target of CDK2/cyclin E in centrosome duplication. Cell 2000, 103:127-140.
35. Tokuyama Y., Horn H.F., Kawamura K., Tarapore P., Fukasawa K. Specific phosphorylation of nucleophosmin on Thr(199) by cyclin-dependent kinase 2-cyclin E and its role in centrosome duplication. J. Biol. Chem. 2001, 276:21529-21537.
36. Bellacosa A., de Feo D., Godwin A.K., Bell D.W., Cheng J.Q., Altomare D.A., Wan M., Dubeau L., Scambia G., Masciullo V., Ferrandina G., Benedetti Panici P., Mancuso S., Neri G., Testa J.R. Molecular alterations of the AKT2 oncogene in ovarian and breast carcinomas. Int. J. Cancer 1995, 64:280-285.
37. Arboleda M.J., Lyons J.F., Kabbinavar F.F., Bray M.R., Snow B.E., Ayala R., Danino M., Karlan B.Y., Slamon D.J. Overexpression of AKT2/protein kinase Bbeta leads to up-regulation of beta1 integrins, increased invasion, and metastasis of human breast and ovarian cancer cells. Cancer Res. 2003, 63:196-206.
38. Yuan Z.Q., Sun M., Feldman R.I., Wang G., Ma X., Jiang C., Coppola D., Nicosia S.V., Cheng J.Q. Frequent activation of AKT2 and induction of apoptosis by inhibition of phosphoinositide-3-OH kinase/Akt pathway in human ovarian cancer. Oncogene 2000, 19:2324-2330.
39. Rychahou P.G., Kang J., Gulhati P., Doan H.Q., Chen L.A., Xiao S.Y., Chung D.H., Evers B.M. Akt2 overexpression plays a critical role in the establishment of colorectal cancer metastasis. Proc. Natl Acad. Sci. USA 2008, 105:20315-20320.
40. Altomare D.A., Wang H.Q., Skele K.L., De Rienzo A., Klein-Szanto A.J., Godwin A.K., Testa J.R. AKT and mTOR phosphorylation is frequently detected in ovarian cancer and can be targeted to disrupt ovarian tumor cell growth. Oncogene 2004, 23:5853-5857.